China Regenerative Medicine International Limited (8158) AI Stock Analysis

• Market Cap: HK$136.91M
• Dividend Yield: N/A
• Average Volume (3M): 157.46K
• Price to Earnings (P/E): 7.7
• Beta (1Y): 0.37
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 34
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): 0.06
• Shares Outstanding: 304,252,470
• 10 Day Avg. Volume: 282,330
• 30 Day Avg. Volume: 157,461
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.97
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: ―

China Regenerative Medicine International Limited's stock demonstrates positive technical momentum, which is a key strength. However, significant financial risks due to revenue volatility, high leverage, and inconsistent cash flows pose challenges. The lack of earnings call data and valuation metrics limits further assessment. Stabilizing financial performance and reducing leverage are crucial for future stock performance improvement.

China Regenerative Medicine International Limited Business Overview & Revenue Model

Company Description

China Regenerative Medicine International Limited, an investment holding company, produces and sells healthcare products and services. The company offers health management services, such as assessment of health situation, treatment for detox, balance of inner body, nourishing organs, and enhancement of immune system; and beauty services comprising non-surgical medical aesthetic services, basic skincare, solutions for youthful skin, hair revitalizing, lines firming, partial remodelling, and intimate repairing services. The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in March 2015. China Regenerative Medicine International Limited was founded in 1995 and is headquartered in Tsim Sha Tsui, Hong Kong.

How the Company Makes Money

China Regenerative Medicine International Limited generates revenue through the sale of its proprietary regenerative medicine products and technologies. The company's key revenue streams include the commercialization of its tissue engineering and cell therapy products, which are used in medical procedures and treatments. Additionally, the company may form strategic partnerships with healthcare institutions, research organizations, and other biotech companies to expand its market reach and enhance its product offerings. Revenue is further supported by licensing agreements and collaborations that leverage the company's expertise in regenerative medicine, allowing for shared research and development efforts and the potential for milestone and royalty payments.

China Regenerative Medicine International Limited Financial Statement Overview

Summary

The company has shown some recovery in profitability with a return to positive net income in 2024 and improved gross profit margin. However, revenue volatility, high leverage indicated by a debt-to-equity ratio of 2.13, and zero operating and free cash flow in 2024 highlight significant financial challenges and risks.

Income Statement

The company has shown improvement in recent years with a return to positive net income in 2024, following a significant loss in 2023. The gross profit margin increased from 27.9% in 2023 to 63.6% in 2024, indicating better cost management. However, revenue has been volatile, with a decline from 2022 to 2023 and a recovery in 2024, yet still below 2021 levels. This instability in revenue and profitability reflects ongoing challenges.

Balance Sheet

The debt-to-equity ratio is notably high at 2.13 in 2024, indicating significant leverage. Stockholders' equity has improved from 2023 to 2024, but remains a concern due to historical volatility. The equity ratio is low at 18.6%, suggesting limited financial cushion. The overall balance sheet reflects a company with high leverage and risk.

Cash Flow

The company reported zero operating and free cash flow in 2024, indicating potential liquidity issues. Despite positive operating cash flow in 2023, the lack of consistent free cash flow is concerning. The inability to sustain positive cash flows may limit growth opportunities and financial flexibility.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
90.62M	69.49M	41.54M	282.90M	182.14M
	Gross Profit
57.65M	19.42M	37.62M	67.73M	41.81M
	EBIT
18.88M	-106.72M	12.29M	64.59M	-37.53M
	EBITDA
29.84M	-95.40M	14.44M	64.66M	-121.84M
	Net Income Common Stockholders
17.75M	-107.70M	4.55M	51.83M	-404.23M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
57.45M	3.33M	1.85M	9.93M	4.77M
	Total Assets
135.71M	185.90M	275.91M	259.14M	152.49M
	Total Debt
53.69M	50.19M	72.01M	35.82M	43.19M
	Net Debt
30.99M	46.86M	70.16M	25.89M	38.43M
	Total Liabilities
110.51M	174.10M	172.00M	147.41M	207.64M
	Stockholders Equity
25.20M	11.79M	103.92M	111.73M	58.13M
Cash Flow		Free Cash Flow
0.00	6.06M	-20.25M	-3.83M	-397.74M
	Operating Cash Flow
0.00	6.34M	-17.65M	-3.02M	-397.74M
	Investing Cash Flow
0.00	-262.00K	-2.59M	9.27M	326.96M
	Financing Cash Flow
0.00	-7.36M	7.32M	-1.39M	67.37M

China Regenerative Medicine International Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.45
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8158, the sentiment is Positive. The current price of 0.45 is above the 20-day moving average (MA) of 0.37, above the 50-day MA of 0.37, and above the 200-day MA of 0.33, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 64.68 is Neutral, neither overbought nor oversold. The STOCH value of 46.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8158.

China Regenerative Medicine International Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
8158	49 Neutral	HK$136.91M	7.71		―	―	―
PIAIF		$126.38B	6.18		7.49%	―	―
SBMFF		$12.60B	51.81	6.14%	1.09%	―	―
CHSYF		$3.52B	10.08	10.17%	0.48%	―	―
LVZPF		$4.34B	12.68	14.56%	3.79%	―	―
SHWGF		$3.49B	12.17	8.95%	4.46%	―	―